Abstract Details

Title Real-World Effectiveness of Ubrogepant Among Participants With Prior Treatment Failure: Subgroup Analysis From the UNIVERSE Study

Topic Headache

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-001

Background The safety and efficacy of ubrogepant have been demonstrated in the phase 3 ACHIEVE trials; however, the effectiveness of ubrogepant in the real-world setting has yet to be fully characterized.

Objective To examine real-world effectiveness of ubrogepant for the acute treatment of migraine in patients who switched to ubrogepant due to the lack of efficacy of their prior acute treatment.

Design/Methods The UNIVERSE (Ubrogepant users’ experience: Patients on ubrogepant, characteristics and outcomes) study is an observational cross-sectional study of US adult users of the Migraine Buddy application who self-reported using ubrogepant for ≥4 prior migraine headaches, including ≥1 dose in the preceding 14 days. Eligible participants completed a 29-question survey assessing patient characteristics, treatment patterns, outcomes, and satisfaction with ubrogepant.

Results Of 302 respondents, 87.4% (n=264) switched to ubrogepant due to their prior treatment’s lack of efficacy. For this subgroup, mean age was 42 years, 89% were female, 35.6% had chronic migraine, and 55.9% previously tried ≥3 triptans. The majority reported being satisfied with ubrogepant for achieving pain relief at 2-hours (76.1%), 4-hours (83.3%), and 24-hours (78.4%) post-dose. A large proportion reported satisfaction for the ability to think clearly (85.2%) and with their return to normal function (84.8%) after ubrogepant treatment. The vast majority (91.7%) reported they were likely to continue ubrogepant use. Analysis of prior and concurrent acute medication revealed reduced use of opioids (-28%), barbiturates (-25%), ergots (-15%), triptans (-55%), nonsteroidal anti-inflammatory drugs (-38%), and other acute medication classes (-37%).

Conclusions Among patients who self-reported lack of efficacy as the reason for prior treatment failure, ubrogepant use was associated with high satisfaction for achieving pain relief, ability to think clearly, and return to normal function. The majority indicated they were likely to continue its use. Ubrogepant was also associated with reductions in opioid and barbiturate use, suggesting additional clinical benefits for users.

Authors/Disclosures
Krutika Jariwala-Parikh, PhD (AbbVie) PRESENTER	Dr. Jariwala-Parikh has received personal compensation for serving as an employee of AbbVie. Dr. Jariwala-Parikh has stock in AbbVie.
Anand R. Shewale (AbbVie)	Anand R. Shewale has received personal compensation for serving as an employee of AbbVie. Anand R. Shewale has stock in AbbVie.
	No disclosure on file
Michael L. Reed, PhD (Vedanta Research)	The institution of Dr. Reed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Reed has received research support from Allergan. The institution of Dr. Reed has received research support from Dr Reddy's Labs/Promius. The institution of Dr. Reed has received research support from Allay Lamp. Dr. Reed has a non-compensated relationship as a Research Analyst with National Headache Foundation that is relevant to AAN interests or activities.
	No disclosure on file
Francois Cadiou, MBA (Healint)	Mr. Cadiou has received personal compensation for serving as an employee of Healint.
	No disclosure on file
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.